This is partly due to the fact that TNBC does not overexpress the common targets of breast cancer treatment including estrogen receptors, progesterone receptors, or human epidermal growth factor receptor 2 (HER-2); therefore, the common breast cancer-targeted therapies cannot be utilized in these patients. Here, ESR1 is linked to breast carcinoma.